SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Abraxane

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved / marketed (legacy product)
Time to market
Already on the market, a long-approved, marketed chemotherapy (US sales began in the mid-2000s); no further approval needed.
Why 2/10
No hard, dated catalyst exists for Abraxane in the next ~12 months, it is already approved and marketed, with zero FDA actions, catalysts, or readouts tied to it in the local data, and it is a minor legacy product inside a ~$129B diversified pharma, so even a favorable development would barely move BMY.
Actionable Insight NEUTRAL

Do not trade BMY on Abraxane, it is a declining, generics-exposed legacy chemotherapy with no scheduled catalyst and immaterial weight in a ~$129B company. If you hold BMY, the stock thesis is driven by the Growth Portfolio (Opdivo, Eliquis, Breyanzi) and pipeline PDUFAs, not this drug; track Abraxane only as a line item within Legacy Portfolio erosion at quarterly earnings.

Price Chart

Loading chart...

Executive Summary

Abraxane (nab-paclitaxel, development code ABI-007) is a long-approved, mature chemotherapy that came to Bristol Myers Squibb through its 2019 acquisition of Celgene (which had bought Abraxis BioScience). Internal SecBot data confirms BMY (NYSE) is the current owner, Abraxane appears in BMY's Q2 2026 earnings-filing drug list, and that the drug is still widely used as a chemotherapy backbone, especially the gemcitabine/Abraxane (GnP) regimen in pancreatic cancer. It sits in BMY's "Legacy Portfolio," which fell 4% year-over-year in Q2 2026 amid generic erosion, and there are no regulatory catalysts scheduled for it.

How It Works

Abraxane is paclitaxel, a classic chemotherapy that stops cancer cells from dividing, wrapped in tiny nanoparticles of human albumin protein. This "protein-bound" packaging lets it be infused without the harsh solvent used in older Taxol, which historically reduced infusion-allergic reactions and allowed different dosing.

Trial Status

No BMS-sponsored registrational trials for Abraxane appear in the ingested pipeline; it is used as an established chemotherapy backbone in outside Phase 2/3 studies (pancreatic cancer gemcitabine/Abraxane combos, triple-negative breast cancer, NSCLC, biliary tract). Local trial/event records show completed and ongoing academic and industry studies combining nab-paclitaxel with newer agents.

The Two-Sided Case

▲ Bull Case3
Fully de-risked and cash-generating: the drug is already approved and marketed, and its owner BMY is financially strong, Q2 2026 revenue of $12.973B beat consensus by 10.5% and full-year guidance was raised (per BMY 8-K filing analysis).
Still a clinically relevant backbone: local trial and event records show nab-paclitaxel remains a standard chemotherapy partner in pancreatic cancer (gemcitabine/Abraxane), TNBC, and NSCLC combination studies, indicating ongoing real-world demand.
The albumin-bound nanoparticle formulation is a genuine differentiator vs. solvent-based paclitaxel (Taxol), the historical rationale for its use.
▼ Bear Case4
Mature, declining legacy asset: BMY's Legacy Portfolio revenue fell 4% YoY in Q2 2026, with the company's filing analysis citing generic erosion on legacy drugs (Revlimid -49%, Pomalyst/Imnovid -71%, Sprycel -27%), Abraxane is not called out as a growth driver.
No catalysts: local data shows zero FDA actions, catalysts, or price-reaction outcomes for Abraxane in the past year-plus, and no BMS-sponsored late-stage trials for it, the drug's defining regulatory binary passed years ago.
Immaterial to the stock: BMY trades at ~$65.31 with a market cap near $129B and a consensus 'hold' (mean price target $64.91 vs. current price, implying roughly -0.5% upside), so Abraxane-specific events would barely move the shares.
Long-running generic/competitor pressure on nab-paclitaxel has eroded pricing and share for years, consistent with its placement in a declining legacy bucket.

Upcoming Catalysts

  • None scheduled for Abraxane itself (no PDUFA, pivotal readout, or label decision in the next ~12 months).
  • Company-level, not drug-level: BMY quarterly earnings will keep reporting Legacy Portfolio erosion including Abraxane; BMY's own pipeline PDUFAs (e.g., iberdomide Aug 17, 2026) are the real stock drivers.
  • Watch whether any partner trial using gemcitabine/Abraxane (e.g., Alpha Tau's pancreatic-cancer IMPACT expansion, per local event records) produces data that could modestly influence Abraxane utilization.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov